CSIMarket Company Name, Ticker, Industry, else..
 
Ampio Pharmaceuticals inc   (NYSEAMER: AMPE)
Other Ticker:  
 
 
Price: $0.0005 $0.00 -80.769%
Day's High: $0.0005 Week Perf: -77.27 %
Day's Low: $ 0.00 30 Day Perf: -77.27 %
Volume (M): 0 52 Wk High: $ 2.91
Volume (M$): $ 0 52 Wk Avg: $0.82
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Ampio Pharmaceuticals Inc
Ampio Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development of therapies for the treatment of inflammatory and metabolic diseases. The company's main goal is to improve the quality of life for patients suffering from these conditions.

Ampio Pharmaceuticals develops its therapies using a proprietary drug delivery technology called Ampion. This technology allows for the targeted delivery of therapeutic compounds to the site of inflammation, which can help reduce pain and inflammation in affected tissues.

The company's pipeline includes several drug candidates that are being developed for various indications, including osteoarthritis, diabetic macular edema, and respiratory diseases. Ampio Pharmaceuticals is currently conducting clinical trials to evaluate the safety and efficacy of these therapies.

In addition to its drug development efforts, Ampio Pharmaceuticals also collaborates with other pharmaceutical companies and research organizations to explore potential collaborations and licensing agreements.

Overall, Ampio Pharmaceuticals is dedicated to advancing innovative therapies that have the potential to make a significant impact on the lives of patients with inflammatory and metabolic diseases.


   Company Address: 9800 Mount Pyramid Court Englewood 80112 CO
   Company Phone Number: 437-6500   Stock Exchange / Ticker: NYSEAMER AMPE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -3.27%    
CPIX        105.08% 
HOOK   -11.55%    
MRUS   -1.53%    
SIGA   -10.77%    
TSVT   -5.67%    
• View Complete Report
   



Ampio Pharmaceuticals Inc

Investors Impressed by Ampio Pharmaceuticals Inc.'s Operating Loss Improvement in Q4 2023



Investors have been pleasantly surprised by recent developments in the stock market, particularly in the healthcare sector. Ampio Pharmaceuticals Inc. (AMPE) has showcased encouraging numbers during the October to December 2023 earnings season. Despite expectations of no significant changes at the top-line, the company's operating loss has improved, hinting at a positive trajectory for future success. Shareholders and market participants are gaining confidence in AMPE's potential, and these promising developments are worth exploring in detail.
Operating Loss Improvement:
During the same period, AMPE displayed a noteworthy reduction in operating loss, from $-2.702 million in Q4 of 2022 to $-2.215 million currently. While it may not be the easiest benchmark, this improvement is substantial and indicative of the company's commitment to growth and stability. Moreover, the company has further narrowed the losses from $-2.220 million to $-2.054 million quarter-on-quarter, boosting expectations of its future performance.
Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals Inc Delivers Genuine Gain in Q3 2023 Financial Report, Despite Operating Loss

During the past week, Ampio Pharmaceuticals Inc stock experienced a significant drop of -14.86%. This decline adds to the company's struggles throughout the year, as its year-to-date performance stands at -56.16%. Furthermore, the stock has reached its 52-week low. These numbers are cause for concern for investors and analysts alike, as they indicate a downward trend for the company.
These recent developments are particularly noteworthy given the ongoing reporting season, which began in July and will continue until September 30, 2023. Many businesses, including those in the Major Pharmaceutical Preparations sector, have been sharing their financial results. Ampio Pharmaceuticals Inc is one of these companies, and it recently reported an operating loss of $-1.4 million for the third quarter of 2023. While an operating loss is never desirable, it is worth noting that this represents an improvement compared to the same period in 2022, where the operating loss was $-7.658 million. This shift in performance could potentially be seen as a positive sign for the company's future.
Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals Inc Struggles with Financial Setbacks and Dwindling Stock Prices in the Second Quarter of 2023


Introduction
The second quarter of 2023 has proven to be challenging for Ampio Pharmaceuticals Inc, a major player in the pharmaceutical preparations sector. With a widening operating shortfall of $-1.56 million and no reported revenue, the company's performance is a cause for concern. Despite some improvements compared to the previous year, Ampio Pharmaceuticals Inc is grappling with increasing deficits and a decline in its stock price. This article delves into the company's financial struggles, underperformance, and the obstacles it must overcome to secure a brighter future.
Operating Shortfall Signals Troubles Ahead
In the April to June 30, 2023 reporting season, Ampio Pharmaceuticals Inc suffered an operating shortfall of $-1.56 million. While there was a slight improvement from the previous year's figure of $-4.988 million, the company's inability to generate revenue is evident and cannot be ignored. The consistently negative operating shortfalls point towards a larger problem within the organization, raising concerns about its long-term viability.
Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals Inc Reports Operating Shortfall for Q1 2023; Decreasing Returns Show Positive Trend

Investors should approach the stock market cautiously, especially when it comes to the Major Pharmaceutical Preparations industry. As reported in the first quarter of 2023, Ampio Pharmaceuticals Inc has incurred an operating shortfall of $-4.399 million due to the absence of any revenue for the financial reporting period of January to March 31, 2023.
Although the productivity in the expansion span has overshadowed the previous three months, it remains a crucial observation to consider. The good news is that the decreasing returns have declined to $-3.978 million from $-5.636 million in the first quarter of 2022, which could potentially help the company to emerge as a standout bellwether in the industry.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com